A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan, Sumatriptan, and Lasmiditan + Sumatriptan [ Time Frame: Baseline through 48 hours after administration of study drug in each period ]

PK: Cmax of Lasmiditan, Sumatriptan, and Lasmiditan + Sumatriptan

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0 ∞]) of Lasmiditan, Sumatriptan, and Lasmiditan + Sumatriptan [ Time Frame: Baseline through 48 hours after administration of study drug in each period ]

PK: AUC(0 ∞) of Lasmiditan, Sumatriptan and Lasmiditan + Sumatriptan

Original Secondary Outcome Measures ICMJE

Same as current

Current Other Pre-specified Outcome Measures

Not Provided

Original Other Pre-specified Outcome Measures

Not Provided

Descriptive Information

Brief Title ICMJE

A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants

Official Title ICMJE

A Randomized, Double-Blind, Four-Period, Crossover Study to Evaluate the Cardiovascular Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Subjects

Brief Summary

The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it when these two drugs are taken together.

This study will last about 21 days, not including the screening. Participants will spend 16 days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is required within 28 days prior to the start of the study.